(Q34820278)

4 August 2017

1 reference

title

Focus on new drugs in development against human cytomegalovirus (English)

1 reference

4 August 2017

0 references

Vincent C Emery

1

0 references

author name string

Aycan F Hassan-Walker

series ordinal

2

1 reference

4 August 2017

publication date

1 January 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

62

1 reference

4 August 2017

issue

13

1 reference

4 August 2017

page(s)

1853-1858

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200262130-00002

4 August 2017

exact match

0 references

cites work

Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease

1 reference

12 December 2020

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

1 reference

12 December 2020

Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56

1 reference

12 December 2020

Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy

1 reference

12 December 2020

Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2.

1 reference

12 December 2020

Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole

1 reference

12 December 2020

Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir

1 reference

12 December 2020

Benzothiadiazine dioxide dibenzyl derivatives as potent human cytomegalovirus inhibitors: synthesis and comparative molecular field analysis.

1 reference

12 December 2020

Novel potential agents for human cytomegalovirus infection: synthesis and antiviral activity evaluation of benzothiadiazine dioxide acyclonucleosides

1 reference

12 December 2020

Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis

1 reference

12 December 2020

Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product

1 reference

12 December 2020

Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir

1 reference

12 December 2020

Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.

1 reference

12 December 2020

Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives

1 reference

12 December 2020

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

1 reference

12 December 2020

10.2165/00003495-200262130-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1024196567

0 references

1 reference